Overview

A Study Of New Medicine (GSK 372475) For The Treatment Of Depression

Status:
Completed
Trial end date:
2008-12-01
Target enrollment:
Participant gender:
Summary
To evaluate the efficacy, safety, and tolerability of GSK372475 compared with placebo in the treatment of outpatient subjects with Major Depressive Disorder (MDD)
Phase:
Phase 2
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Venlafaxine Hydrochloride